Supplementary Data files S1 a_f from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy

Excel spreadsheets showing: (S1a) the differential expression analysis between mesenchymal vs proneural tumors; (S1b) the differential expression analysis between classical vs mesenchymal tumors; (S1c) the differential expression analysis between classical vs proneural tumors; (S1d) classification of tumor samples based on the RNA-Seq results into the three TCGA molecular subtypes (according to the GlioVis algorithms KNN, SVM, and ssGSEA) and classification according to the IGS clusters; (S1e) immunohistochemical results of samples classified in the three TCGA molecular subtypes (according to the GlioVis algorithms KNN, SVM, and ssGSEA) and IGS clusters; and (S1f) results of the gene fusion analysis in the tumor samples, the molecular subtype of the tumor (according to the GlioVis algorithms KNN, SVM, and ssGSEA), and the tumor IGS clusters